Advertisement
Screener

Beam Therapeutics Inc. (BEAM) Increase (Decrease) in Prepaid Expense and Other Assets

2.8 / 5 stars · 68/120 Roast Me

Beam Therapeutics Inc. Increase (Decrease) in Prepaid Expense and Other Assets

Beam Therapeutics Inc. (BEAM) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-04

  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$29.53M.
  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $31.86M.
  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$59.00K, a 100.76% decline year-over-year.
  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.63M.
  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$4.51M, a 184.33% decline from fiscal 2024.
  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $5.35M, a 19.19% decline from fiscal 2023.
  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $6.62M, a 14.63% decline from fiscal 2022.
  • Beam Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $7.75M.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month as first filed
2026-06-30-$29.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$2.33M
10-Q · filed 2026-08-04
$2.27M
derived: sum of 3 quarters · filed 2026-08-04
$644.00K
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$31.86M
10-Q · filed 2026-05-07
$31.80M
derived: sum of 2 quarters · filed 2026-05-07
$30.18M
derived: sum of 3 quarters · filed 2026-05-07
$27.40M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$59.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$1.68M
derived: sum of 2 quarters · filed 2026-02-24
-$4.46M
derived: sum of 3 quarters · filed 2026-08-04
-$4.51M
10-K · filed 2026-02-24
2025-09-30-$1.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$4.40M
derived: sum of 2 quarters · filed 2026-08-04
-$4.45M
10-Q · filed 2025-11-04
$3.35M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$2.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$2.83M
10-Q · filed 2026-08-04
$4.98M
derived: sum of 3 quarters · filed 2026-08-04
$3.24M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$49.00K
10-Q · filed 2026-05-07
$7.76M
derived: sum of 2 quarters · filed 2026-05-07
$6.01M
derived: sum of 3 quarters · filed 2026-05-07
-$232.00K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$7.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$6.06M
derived: sum of 2 quarters · filed 2026-02-24
-$183.00K
derived: sum of 3 quarters · filed 2026-02-24
$5.35M
10-K · filed 2026-02-24
2024-09-30-$1.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$7.99M
derived: sum of 2 quarters · filed 2025-11-04
-$2.46M
10-Q · filed 2025-11-04
-$5.88M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30-$6.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$714.00K
10-Q · filed 2025-08-05
-$4.14M
derived: sum of 3 quarters · filed 2026-02-24
-$571.00K
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31$5.53M
10-Q · filed 2025-05-06
$2.11M
derived: sum of 2 quarters · filed 2026-02-24
$5.67M
derived: sum of 3 quarters · filed 2026-02-24
$3.75M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31-$3.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$143.00K
derived: sum of 2 quarters · filed 2026-02-24
-$1.79M
derived: sum of 3 quarters · filed 2026-02-24
$6.62M
10-K · filed 2026-02-24
$6.47M
10-K · filed 2024-02-27
2023-09-30$3.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
$1.64M
derived: sum of 2 quarters · filed 2024-11-05
$10.04M
10-Q · filed 2024-11-05
$10.60M
derived: sum of 4 quarters · filed 2025-02-25
2023-06-30-$1.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$6.48M
10-Q · filed 2024-08-06
$7.04M
derived: sum of 3 quarters · filed 2025-02-25
$7.27M
derived: sum of 4 quarters · filed 2025-02-25
2023-03-31$8.40M
10-Q · filed 2024-05-07
$8.97M
derived: sum of 2 quarters · filed 2025-02-25
$9.20M
derived: sum of 3 quarters · filed 2025-02-25
$6.97M
derived: sum of 4 quarters · filed 2025-02-25
2022-12-31$561.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$796.00K
derived: sum of 2 quarters · filed 2025-02-25
-$1.43M
derived: sum of 3 quarters · filed 2025-02-25
$7.75M
10-K · filed 2025-02-25
2022-09-30$235.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$1.99M
derived: sum of 2 quarters · filed 2023-11-08
$7.19M
10-Q · filed 2023-11-08
$7.18M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30-$2.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$6.96M
10-Q · filed 2023-08-08
$6.94M
derived: sum of 3 quarters · filed 2024-02-27
$3.10M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31$9.19M
10-Q · filed 2023-05-10
$9.17M
derived: sum of 2 quarters · filed 2024-02-27
$5.33M
derived: sum of 3 quarters · filed 2024-02-27
$6.07M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31-$13.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
-$3.85M
derived: sum of 2 quarters · filed 2024-02-27
-$3.11M
derived: sum of 3 quarters · filed 2024-02-27
-$746.00K
10-K · filed 2024-02-27
2021-09-30-$3.84M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$3.10M
derived: sum of 2 quarters · filed 2022-11-07
-$733.00K
10-Q · filed 2022-11-07
$1.33M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$741.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$3.11M
10-Q · filed 2022-08-09
$5.17M
derived: sum of 3 quarters · filed 2023-02-28
$4.62M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$2.37M
10-Q · filed 2022-05-09
$4.42M
derived: sum of 2 quarters · filed 2023-02-28
$3.88M
derived: sum of 3 quarters · filed 2023-02-28
$4.53M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$2.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$1.51M
derived: sum of 2 quarters · filed 2023-02-28
$2.17M
derived: sum of 3 quarters · filed 2023-02-28
$5.73M
10-K · filed 2023-02-28
2020-09-30-$548.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$108.00K
derived: sum of 2 quarters · filed 2021-11-08
$3.67M
10-Q · filed 2021-11-08
$2.87M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$656.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
$4.21M
10-Q · filed 2021-08-10
$3.42M
derived: sum of 3 quarters · filed 2022-02-28
$4.68M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$3.56M
10-Q · filed 2021-05-11
$2.76M
derived: sum of 2 quarters · filed 2022-02-28
$4.02M
derived: sum of 3 quarters · filed 2022-02-28
$4.39M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31-$797.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$461.00K
derived: sum of 2 quarters · filed 2022-02-28
$833.00K
derived: sum of 3 quarters · filed 2022-02-28
$1.26M
10-K · filed 2022-02-28
2019-09-30$1.26M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
$1.63M
derived: sum of 2 quarters · filed 2020-11-10
$2.06M
10-Q · filed 2020-11-10
2019-06-30$372.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
$797.00K
10-Q · filed 2020-08-12
2019-03-31$425.00K
10-Q · filed 2020-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
NOVAVAX INC (NVAX)United States$1.748B-6.26